| Abatacept |
| ACE Inhibitors |
| Acetazolamide |
| Adalimumab |
| Albuterol |
| Aminophylline |
| Anesthesia |
| Angiotensin Receptor Blockers |
| Anti-Asthmatic Agents |
| Anti-Diabetic Agents, Intravenous |
| Anti-Diabetic Agents, Oral |
| Anti-Reflux Medications |
| Antibiotic Injectables |
| Antihypertensive Medications |
| Antineoplastics |
| Antipsychotics |
| Azathioprine |
| Beta Blockers |
| Calcium Channel Blockers |
| Chemotherapy |
| Citrate Exposures |
| COVID-19 Medications |
| Cyclophosphamide |
| Deflazacort |
| Fludrocortisone |
| Furosemide |
| Intravenous Fluids |
| Intravenous Fluids, Semantic Clinical Drug Form |
| Loop Diuretic |
| Mycophenolate |
| Nephrotoxic Chemotherapy |
| Opioids |
| Paxlovid |
| Proton-Pump Inhibitors |
| Renin-Angiotensin-Aldosterone (RAAS) System Blockers for PRESERVE |
| Renin-Angiotensin-Aldosterone System (RAAS) Blockers as Treatment Regimen for HSP Nephritis |
| Rituximab |
| Supplemental Oxygen |
| Systemic Steroids |
| Tacrolimus and Cyclosporine |
| Thiazides and Diuretics, Oral |
| Thiazides for PRESERVE |
| Topiramate |
| Vasopressors |
| Vitamin B6 |
| Zonisamide |
